Preliminary results from TRASTYVERE study: A retrospective analysis of heavily pretreated HER2-positive metastatic breast cancer patients treated in Spain with lapatinib plus trastuzumab as compassive therapy

被引：0
|
作者：
Gavila, J. [1 ]
Bermejo, B. [2 ]
Manso, L. [3 ]
Munoz, E. [4 ]
Anton, A. [5 ]
Brunet, J. [6 ]
Rodriguez, C. A. [7 ]
Santaballa, A. [8 ]
Cortes, J. [4 ,9 ]
Llombart, A. [9 ,10 ]
机构：
[1] Inst Valenciano Oncol, Valencia, Spain
[2] Hosp Clin Univ Valencia, Valencia, Spain
[3] Hosp 12 Octubre, Madrid, Spain
[4] VHIO, Barcelona, Spain
[5] Hosp Univ Miguel Servet, Zaragoza, Spain
[6] Inst Catala Oncol Girona, Girona, Spain
[7] Hosp Univ Salamanca IBSAL, Salamanca, Spain
[8] Hosp Univ La Fe Valencia, Valencia, Spain
[9] Med Scientia Innovat Res MedSIR ARO, Oncol, Barcelona, Spain
[10] Hosp Arnau de Vilanova Valencia, Valencia, Spain
来源：
EUROPEAN JOURNAL OF CANCER | 2014年 / 50卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S181 / S181
页数：1
相关论文
共 50 条
  • [1] Preliminary results from TRASTYVERE study: A retrospective analysis of HER2-positive (HER2) metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T).
    Gavila, Joaquin
    Bermejo, Begona
    Manso, Luis
    Munoz, Eva
    Anton, Antonio
    Brunet, Joan
    Rodriguez-Lescure, Alvaro
    Augusto Rodriguez, Cesar
    Santaballa, Ana
    Sanchez-Rovira, Pedro
    de la Haba-Rodriguez, Juan
    Santisteban, Marta
    Ruiz Borrego, Manuel
    Cortes, Javier
    Llombart-Cussac, Antonio
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [2] TRASTYVERE study: A retrospective analysis of HER2-positive metastatic breast cancer (MBC) patients treated in Spain with lapatinib (L) plus trastuzumab (T)
    Gavila, Joaquin
    Bermejo, Begona
    Rodriguez-Lescure, Alvaro
    Lao Romera, Juan
    Manso, Luis
    Brunet, Joan
    Munoz, Eva
    Santisteban, Marta
    Rodriguez, Cesar A.
    Santaballa, Ana
    de la Haba, Juan
    Sanchez-Rovira, Pedro
    Ruiz-Borrego, Manuel
    Angel Garcia-Saenz, Jose
    Cortes, Javier
    Llombart, Antonio
    CANCER RESEARCH, 2015, 75
  • [3] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    Gavila, J.
    De La Haba, J.
    Bermejo, B.
    Rodriguez-Lescure, A.
    Anton, A.
    Ciruelos, E.
    Brunet, J.
    Munoz-Couselo, E.
    Santisteban, M.
    Rodriguez Sanchez, C. A.
    Santaballa, A.
    Sanchez Rovira, P.
    Garcia Saenz, J. a.
    Ruiz-Borrego, M.
    Guerrero-Zotano, A. L.
    Huerta, M.
    Cotes-Sanchis, A.
    Lao Romera, J.
    Aguirre, E.
    Cortes, J.
    Llombart-Cussac, A.
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2020, 22 (03): : 420 - 428
  • [4] A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study
    J. Gavilá
    J. De La Haba
    B. Bermejo
    Á. Rodríguez-Lescure
    A. Antón
    E. Ciruelos
    J. Brunet
    E. Muñoz-Couselo
    M. Santisteban
    C. A. Rodríguez Sánchez
    A. Santaballa
    P. Sánchez Rovira
    J. Á. García Sáenz
    M. Ruiz-Borrego
    A. L. Guerrero-Zotano
    M. Huerta
    A. Cotes-Sanchís
    J. Lao Romera
    E. Aguirre
    J. Cortés
    A. Llombart-Cussac
    Clinical and Translational Oncology, 2020, 22 : 420 - 428
  • [5] Lapatinib plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Watanabe, J.
    Hamauchi, S.
    Higashi, Y.
    Onozawa, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [6] Lapatinib with trastuzumab for heavily treated HER2-positive metastatic breast cancer (mBC).
    Sotelo, Miguel J.
    Manso, Luis
    Garcia Saenz, Jose Angel
    Ciruelos, Eva M.
    Moreno, Fernando
    Mendiola, Cesar
    Callata, Hector
    Ghanem, Ismael
    Cabezas, Santiago
    Gonzalez-Larriba, Jose-Luis
    Diaz Rubio, Eduardo
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [7] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Osako, Tomo
    Ito, Yoshinori
    Takahashi, Shunji
    Tokudome, Nahomi
    Iwase, Takuji
    Hatake, Kiyohiko
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2008, 62 (01) : 159 - 164
  • [8] Efficacy and safety of trastuzumab plus capecitabine in heavily pretreated patients with HER2-positive metastatic breast cancer
    Tomo Osako
    Yoshinori Ito
    Shunji Takahashi
    Nahomi Tokudome
    Takuji Iwase
    Kiyohiko Hatake
    Cancer Chemotherapy and Pharmacology, 2008, 62 : 159 - 164
  • [9] Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC).
    Salvador, Javier
    Ruiz Borrego, Manuel
    Valero, Maria
    Bayo, Juan L.
    De La Cruz-Merino, Luis
    Carabantes, FRancisco
    Rodriguez de la Borbolla, Maria
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Retreatment with trastuzumab after progression on lapatinib-based therapy in heavily pretreated HER2-positive metastatic breast cancer: A monoinstitutional experience
    Spazzapan, S.
    Crivellari, D.
    Tumolo, S., V
    Russo, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
12345